Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So we’re super excited |
| ClearNote has an epigenomic platform that we believe is gaining traction with biopharma customers by allowing those partners to detect cancer earlier, monitor disease progression, and understand mechanisms of resistance with the aim of identifying promising drug targets and biomarkers |
| 2023 was a year of strong performance for Personalis, as we build a culture of execution and winning |
| To those ends, we expect our revenue to decline this year from Natera, but expect our margins to improve and are optimistic we put in place the foundation to continue the relationship over time |
| The 4.3 percentage points of margin expansion was primarily due to favorable operating leverage from the 13% increase in revenue volume |
| We think the 10 give us the good cornerstone to drive the right kinds of submissions that will get us Medicare coverage, because we think these data sets are strong and robust and comprehensive |
| With momentum across our business, we’re excited for what lies ahead |
| And we’re really excited about that indication, because the opportunity to deescalate patients is really exciting with an ultra-sensitive approach |
| Remember that, the strategy here was to focus on the indications where we thought we could gain significant traction with an ultra-sensitive approach and add really tremendous value by finding cancer earlier, allowing us to escalate patients to therapy quicker that actually could yield big results |
| The clinical evidence is coming together to demonstrate that an ultra-sensitive test provides tremendous value to patients, doctors, and partners, and that puts Personalis in a position to grow rapidly |
| Indeed, here in the first quarter, we’ve already booked record new orders for NeXT Personal and we believe it will be a driver of revenue moving forward an important way for us to deepen the clinical utility of NeXT Personal |
| This is another exciting opportunity to continue to grow our biopharma customer base |
| This holds out the promise that NeXT Personal could be an excellent approach to optimize biopharma trials |
| This is an exciting relationship that paves the way to achieving commercial traction in a capital efficient manner |
| So that’s super exciting |
| In this relationship, Personalis’ biopharma sales team will bring ClearNote’s products to our customers, which provide another growth vehicle |
| So as that starts to come together, we expect the revenue for our NeXT Personal and clinical market to really start to grow and get traction, and that’s a big driver |
| The uptake has been phenomenal |
| So that’s – and you’ll see that that gave us confidence in talking about our $100 million in 2025 plan, which we’re excited about |
| We think it’s a significant opportunity |
| Now, while we’ve made strides with our first growth engine, our Win-in-MRD strategy to establish NeXT Personal was a leading MRD test, we’ve also made progress with our second growth engine, leveraging our ImmunoID NeXT platform to deepen relationships with biopharma customers who use the offering to pioneer new therapies and enterprise customers as they develop or ramp up volume for tissue-informed products |
| And we expect that to yield efforts and significant revenue, because we’re also growing the commercial traction with our partner Tempus |
| We are thrilled that Tempus selected us as their MRD tumor-informed choice to offer to their customers |
| We have helped power this program with the VA for years and we’re excited to continue the work in 2024 |
| I want to especially thank my colleagues and our team at Personalis for their extraordinary efforts in 2023 to navigate through a challenging climate as we reduced headcount, grew our revenue, launched new products, achieved coverage, and showcased truly transformative clinical data |
| We are engaged with most of the world’s top biopharma customers and have received positive feedback on our platform |
| So we’re super excited about where we are and we’ll have to a great start |
| Third, we are deepening and expanding our relationships with our enterprise customers such as Natera and the VA MVP with our Personalis and side approach that allows customers to leverage our technology and ability to produce cost-effective assays |
| We are the first ultra-sensitive test-to-market and the adoption of our test has been rapid, and indeed it’s exceeding our initial targets |
| We are laser focused on adding value to biopharma customers with a comprehensive suite of products and services and accelerating our growth rate |
| Statement |
|---|
| Our full year revenue guidance of $73 million to $75 million includes an estimated revenue decline of approximately 25% from Natera, which reduces our total revenue by 10% to 12% |
| In addition, we expect net loss of approximately $80 million, which is $28 million lower than the loss of $108 million in 2023 |
| Excluding the employee severance costs, operating expenses were $25.1 million and decreased $9.3 million from the same period last year |
| In terms of the biopharma landscape, so over the past couple of years, there had been some slowdowns and trials and things of that nature |
| The fourth quarter net loss included $4 million for employee severance cost and also an additional $4 million of non-cash expense related to the fair value accounting of the outstanding warrants issued to Tempus |
| Net loss for the fourth quarter was $26.6 million compared with $31.1 million for the same period of the prior year |
| So, we’ll be running in a relatively low volume situation |
| These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations |
| The full year net loss included $8.1 million of employee severance costs, $5.6 million of a lease impairment write-down for the Menlo Park facility previously vacated, and a $4 million expense related to the fair value accounting of the outstanding warrants issued to Tempus |
| I apologize, I might have missed some parts jumping around on calls here |
Please consider a small donation if you think this website provides you with relevant information